We read with interest the article by Kassan and Moutsopoulos1 about the clinical manifestations of Sjögren syndrome. We are surprised that the authors did not mention celiac disease (CD) as an association. Indeed, Iltanen et al2 found that in a population of 34 patients with primary Sjögren syndrome, 5 patients (14.7%) had CD. This high prevalence has been confirmed by Szodoray et al,3 who observed a CD prevalence of 4.5% in a population of 111 patients with Sjögren syndrome, whereas the prevalence of CD is estimated to be 0.45% in the general population. This is of interest because the authors observed antimitochondrial antibodies in 7% of their patients.1 In those cases, the histopathological appearance is similar to that of early (stage 1) primary biliary cirrhosis. We know that the prevalence of CD in patients with primary biliary cirrhosis is 10-fold higher than that in the general population.4 Consequently, it seems to us that CD must be evaluated in patients with Sjögren syndrome with a screening of antiendomysial (IgA) antibodies as well as immunoglobulin (IgA, IgG, and IgM) dosage, since at least 5% to 10% of patients with CD have an IgA deficiency.5 In these cases, we can test IgG antitransglutaminase antibodies. Screening for CD in such patients is of importance when considering the risk of small bowel adenocarcinomas and lymphomas in patients with CD.6